Cephalogics is developing a noninvasive portable imaging system to provide clinicians with valuable measures of cerebral perfusion status in brain-injured patients.

Undetected perfusion deficits lead to ischemia. Cephalogics detects perfusion deficits and enables early interventions to help avoid ischemia and associated adverse outcomes.


Compact, convenient and easy to use, the Cephalogics system utilizes Diffuse Optical Tomography (DOT) technology to provide bedside imaging of multiple cerebral vascular regions.

Each compact sensor array consists of a high-density arrangement of near-infrared light sources and detectors to provide hundreds of simultaneous spatially resolved measurements. These measurements are processed in real time by proprietary algorithms to produce spatial maps of cerebral tissue oxygen saturation and other perfusion measures.

Cephalogics' technology is the result of a partnership between Allied Minds and Dr. Joseph P. Culver at Washington University in St. Louis. Dr. Culver is a Professor in the Department of Radiology and a Diffuse Optical Tomography expert.



Cephalogics Awarded a US Patent for Its High-Density Diffuse Optical Tomography System

Boston, MA (January 17, 2017) — Cephalogics today announced that it was granted US Patent 9,498,134 B1 for its High-Density Diffuse Optical Tomography (HD-DOT) system, which is designed to deliver real-time brain-specific measurements and imaging of cerebral perfusion status in brain-injured patients.

Read More


Cephalogics Demonstrates Repeatability of Brain Imaging Results in Visual Stimulation Study

Boston, MA (October 18, 2016) — Cephalogics today announced that it was able to demonstrate repeatability of brain images in healthy subjects in their visual stimulus study.

Read More


Cephalogics Announces Results of in vivo Studies that Demonstrate the Ability of its Compact Perfusion Imaging System to Identify and Track Brain Perfusion Deficits

Boston, MA (September 19, 2016) — Cephalogics announced study results from two in vivo studies that demonstrated the imaging capability of the company's compact portable non-invasive brain perfusion imaging system to identify and track perfusion deficits in humans and pigs.

Read More


Cephalogics' Compact Brain Imaging System Demonstrates Ability to Non-Invasively Measure Small Perfusion Changes Caused by Visual Stimulation

Boston, MA (June 27, 2016) — Cephalogics, an Allied Minds company (LSE: ALM), today announced study results showing that its High-Density Diffuse Optical Tomography (HD-DOT) system is capable of measuring and monitoring very small, focal changes in cortical perfusion resulting from visual stimulation in healthy volunteers.

Read More


Cephalogics Announces Study Results That Demonstrate the Accuracy and Sensitivity of Its Portable Brain Perfusion Imaging System

Boston, MA (May 6, 2016) - Cephalogics today announced study results from a blood-phantom platform that demonstrated the accuracy and sensitivity of the company's non-invasive, portable brain perfusion imaging system that is designed to provide continuous bedside monitoring of patients suffering from stroke or traumatic brain injury.

Read More


   The Optical Society of America: Biomedical Optics conference, Ft Lauderdale, FL, April 25-28, 2016
View blood phantom study abstract and poster


   The Organization for Human Brain Mapping conference, Geneva Switzerland, June 26-30, 2016
View retinotopy visual stimulation study abstract and poster


   The Neurocritical Care Society conference, National Harbor, MD, September 15– 18, 2016
View hyperventilation and vascular occlusion study abstracts and posters


   The Society for functional Near Infrared Spectroscopy, Paris France October 13– 16, 2016
View extended retinotopy visual stimulation study abstract and poster


Jeff Caputo

CEO and Board Member

Jeff Caputo brings 14 years of medical device experience in neuromonitoring and has been leading Cephalogics since 2010. Before joining Cephalogics full time in 2013, Jeff was the Director of Life Sciences at Allied Minds (IPO) where he was focused on running early-stage companies as well as sourcing and and creating new companies. Previously, Jeff spent 8 years working for Covidien (acquired by Medtronic) and Aspect Medical Systems (acquired by Covidien) in a variety of roles in sales, marketing, and strategic alliances. Jeff earned his BA degree in Biology and Psychology from St. Olaf College and an MBA degree in Venture Capital and Entrepreneurial Management from Boston College Carroll School of Management.

Omar Amirana, MD

SVP, Life Sciences, Allied Minds and Cephalogics Board Member

Omar Amirana is a Senior Vice President of Allied Minds. Previously, Omar was a Partner at Oxford Bioscience Partners, a Boston-based venture capital firm. There, he sourced and led the Series A investment in nFocus Neuromedical, which commercialized a catheter-based aneurysm therapy and was sold to Covidien. Currently on the board of Cardiofocus (AF catheter ablation), Omar has also served on the boards of Flowmedica (renal therapy; sold to AngioDynamics), SmartPill (GI capsule technology; sold to Given Imaging), Coherex (catheter closure of LAA and PFO), Mitralign (percutaneous heart valve repair), and Cambridge Endoscopic Devices (articulating laparoscopic surgical tools). He served as the Vice President of Business Development at St. Jude Medical, and was also co-founder of Cardima (AF ablation; IPO) and Resolution Medical (cardiac mapping), based in Silicon Valley. Omar earned a BS in Mechanical Engineering from Tufts University and an MD from Eastern Virginia Medical School.

Russ Herrig

Vice President of Engineering

Russ Herrig brings over 30 years of medical device experience and has been leading engineering efforts at Cephalogics since 2011. Before joining Cephalogics, Russ was Director of Software Engineering at Covidien after serving as Senior Director of Emerging Technologies Engineering at Aspect Medical prior to its purchase by Covidien. Previously Russ worked at a medical device startup and at a biotech start up after beginning his career at Haemonetics where he spent 18 years in various Research and Development roles rising to VP of R&D. Russ earned his BS in Biomedical Sciences from Iowa State University and his MS in electrical engineering from Worcester Polytechnic Institute.

Chandran Seshagiri, PhD

Lead Research Scientist

Dr Seshagiri brings over 9 years of medical device experience in neuromonitoring and has been the Lead Research Scientist at Cephalogics since 2013. Before joining Cephalogics, Dr Seshagiri was Principal Research Scientist in the Advanced Research division of Covidien's Respiratory & Monitoring Systems group where he worked on developing new patient monitoring technologies and defining strategic technology targets. He previously worked at Aspect Medical Systems (acquired by Covidien) where he developed a novel EEG-based index of intraoperative patient responsiveness and assisted with initial commercialization efforts. He is a an author on more than 25 journal articles and conference presentations. Dr Seshagiri earned his BA in Physics from Rice University and his Ph.D. from the Harvard-MIT Division of Health Sciences and Technology.

Bertan Hallacoglu, PhD

Research and Development Scientist

Dr Hallacoglu brings over 8 years of R&D experience in optical instrumentation and tissue oximetry. Dr Hallacoglu joined Cephalogics in 2013 and has been focused on developing algorithms and experimental tests in a variety of environments. In addition, he has been involved with product development, research strategy, and business development activities. Before joining Cephalogics, Dr. Hallacoglu served as a research assistant at Tufts University in the Diffuse Optics Laboratory, where he developed novel cerebral oximetry methods involving near-infrared devices, photon migration models of turbid media, and optimization algorithms. He is a named inventor and an author of more than 25 scientific publications in that field. Dr. Hallacoglu earned his bachelor's degree in Electronic Engineering from Wentworth Institute of Technology, a master's degree in Electrical Engineering and a Ph.D. in Biomedical Engineering from Tufts University.

Tanmayi Oruganti

Algorithm Developer

Tanmayi Oruganti brings 3 years of medical device experience and has been building and testing algorithms at Cephalogics since 2015. Before joining Cephalogics, she worked as a Scientist at TomoWave Laboratories where she was involved in the research and development of a 3D breast imaging system based on the principles of photoacoustic imaging and tomography. Tanmayi earned her bachelors in Electronics and Telecommunications Engineering from the Australian National University and her MS in Physics and Engineering in Medicine from University College London.

Cephalogics, LLC is a subsidiary of Allied Minds, an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.